Alnylam Pharmaceuticals Inc. (ALNY) Stock Rating Reaffirmed by Cowen and Company
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reiterated by investment analysts at Cowen and Company in a research note issued to investors on Saturday. They presently have a $100.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $150.00. Cowen and Company’s price target suggests a potential upside of 191.80% from the company’s previous close.
A number of other research firms have also commented on ALNY. JPMorgan Chase & Co. lowered Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $83.00 to $51.00 in a research report on Thursday. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 25th. FBR & Co reiterated an “outperform” rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 27th. Chardan Capital upped their price target on Alnylam Pharmaceuticals from $77.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Jefferies Group reduced their price target on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. Alnylam Pharmaceuticals has a 12-month low of $33.16 and a 12-month high of $110.75. The company’s 50 day moving average price is $70.69 and its 200-day moving average price is $66.05. The company’s market capitalization is $2.94 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter in the previous year, the company posted ($0.85) EPS. The business’s revenue was up .2% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.00% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of ALNY. Nisa Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $128,000. Janney Montgomery Scott LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $223,000. Seven Eight Capital LLC increased its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $175,000. Finally, BlueMountain Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.